Clinical characteristics of rare CFTR mutations causing cystic fibrosis in Polish population

More than 2000 mutations have been identified since the discovery of the CFTR gene in 1989. However, only 346 mutations have been classified as cystic fibrosis (CF)‐causing mutations. Due to the increasing number of mutations and poor correlation between the genotype and phenotype, there is an urgent need to determine the mutations that are pathogenic, nonpathogenic, or lead to variable symptoms.

[1]  C. Castellani,et al.  ECFS best practice guidelines: the 2018 revision. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  C. Kuehni,et al.  Feasibility and normal values of an integrated conductivity (Nanoduct™) sweat test system in healthy newborns. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  O. Sommerburg,et al.  The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  J. Nick,et al.  Diagnosis of Cystic Fibrosis in Nonscreened Populations , 2017, The Journal of pediatrics.

[5]  Margaret Rosenfeld,et al.  Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation , 2017, The Journal of pediatrics.

[6]  D. Sands,et al.  Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience. , 2015, Developmental period medicine.

[7]  Sarah Jane Schwarzenberg,et al.  European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[8]  S. Baker,et al.  Evolution of pancreatic function during the first year in infants with cystic fibrosis. , 2013, The Journal of pediatrics.

[9]  A. Sobczyńska-Tomaszewska,et al.  Newborn screening for cystic fibrosis: Polish 4 years’ experience with CFTR sequencing strategy , 2012, European Journal of Human Genetics.

[10]  A. Nowakowska,et al.  Bilateral sweat tests with two different methods as a part of cystic fibrosis newborn screening (CF NBS) protocol and additional quality control. , 2010, Folia histochemica et cytobiologica.

[11]  A. Nowakowska,et al.  Cystic fibrosis newborn screening enables diagnosis of elder siblings of recalled infants--additional benefit. , 2010, Folia histochemica et cytobiologica.

[12]  A. Munck,et al.  The importance of sweat testing for older siblings of patients with cystic fibrosis identified by newborn screening. , 2009, The Journal of pediatrics.

[13]  O. Sommerburg,et al.  European best practice guidelines for cystic fibrosis neonatal screening. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[14]  A Munck,et al.  A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  C. Clavel,et al.  CFTR genotypes in patients with normal or borderline sweat chloride levels , 2003, Human mutation.

[16]  J. Zieleński.  Genotype and Phenotype in Cystic Fibrosis , 2000, Respiration.

[17]  X. Estivill,et al.  Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe , 2000, Human Genetics.

[18]  X. Estivill,et al.  [Analysis of mutations in the CFTR gene in patients diagnosed with cystic fibrosis in Poland]. , 2000, Medycyna wieku rozwojowego.

[19]  L. Tsui,et al.  Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. , 1991, Genomics.